病理反应和瘤流体免疫特征预测新辅助化疗后非小细胞肺癌的长期存活率
Shuaibo Wang1, Xujie Sun2, Jiyan Dong2
1Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Cellular oncology (Dordrecht, Netherlands)
|February 6, 2024
概括
一种新的新辅助性病理学等级 (NPG) 与淋巴结站 (nS) 结合,更好地预测接受新辅助性化疗的非小细胞肺癌 (NSCLC) 患者的结果. 这种方法改善了治疗有效性的患者分层.
科学领域:
- 在瘤学瘤学.
- 病理学 病理学 病理学
- 癌症研究 癌症研究
背景情况:
- 主要病理反应 (MPR) 是非小细胞肺癌 (NSCLC) 后新辅助疗法的总生存 (OS) 的替代物.
- 在新辅助疗法后,预后组织学特征和最佳N描述器需要进一步定义.
研究的目的:
- 在NSCLC中确定预后组织学特征和新辅助疗法后的最佳N描述符.
- 评估MPR的预后意义,并确定新的预测标记.
主要方法:
- 对368名接受新辅助化疗 (NAC) 和手术治疗的NSCLC患者的回顾性分析.
- 综合审查剩余可活性瘤百分比,淋巴结状况和瘤内炎症.
- 主要终点:整体存活率 (OS).
主要成果:
- 主要瘤中的MPR与改善的OS和DFS相关.
- 在缺乏MPR的瘤中,免疫激活的表型显示出与MPR患者相似的生存结果.
- 新辅助病理等级 (NPG),结合MPR和免疫表型,确定了受益于NAC.的患者.
- 与阳性淋巴结站数 (nS) 集成的NPG表现出优越的预后能力,超过OS的ypTNM分期.
结论:
- 与NS集成的NPG提供了一种实用且强大的方法,用于NSCLC的新辅助化疗中患者分层.
- 这种综合方法可以提高对治疗反应和患者结果的评估.
相关概念视频
02:17The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
01:27Tumor Immunotherapy
526
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526